Evidence map›Paper›PMID 33309058›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021

Amphotericin B induces epithelial voltage responses in people with cystic fibrosis.

Rajeev S Chorghade, Bo Ram Kim, Janice L Launspach, Philip H Karp, Michael J Welsh, Martin D Burke

Abstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. New Therapies to Correct the Cystic Fibrosis Basic Defect.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rajeev S ChorghadeDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Bo Ram KimDepartment of Internal Medicine and HHMI, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Janice L LaunspachDepartment of Internal Medicine and HHMI, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Philip H KarpDepartment of Internal Medicine and HHMI, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Michael J WelshDepartment of Internal Medicine and HHMI, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA; Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Martin D BurkeDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana IL, USA; Arnold and Mabel Beckman Institute, University of Illinois at Urbana-Champaign, Urbana IL, USA; Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Champaign, IL 61820, USA; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana IL, USA. Electronic address: mdburke@illinois.edu.

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Respiratory virus infection in early cystic fibrosis lung diseaseP01HL091842 · NHLBI · UNIVERSITY OF IOWA · PI STOLTZ, DAVID A · 2008 to 2022
$34.2M
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
Pathology CoreP01HL152960 · NHLBI · UNIVERSITY OF IOWA · PI MCCRAY, PAUL B · 2020 to 2024
$11.6M
Molecular Prosthetics and Lego ChemistryR35GM118185 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Martin D Burke · 2016 to 2026
$6.6M
Howard Hughes Medical InstituteNHLBI NIH HHS P01 HL091842NHLBI NIH HHS P01 HL152960NIDDK NIH HHS P30 DK054759NIEHS NIH HHS P30 ES005605NIGMS NIH HHS R35 GM118185
6 · The paper itself

Abstract

backgroundApproximately 10% of people with cystic fibrosis (CF) have mutations that result in little to no CFTR production and thus cannot benefit from CFTR modulators. We previously found that Amphotericin B (AmB), a small molecule that forms anion channels, restored HCO

methodsTo determine whether AmB can impact physiology in people with CF, we first tested whether Fungizone, a clinically approved AmB formulation, could cause electrophysiological effects consistent with anion secretion in primary cultures of CF airway epithelia. We then evaluated the capacity of AmB to change nasal potential difference (NPD), a key clinical biomarker, in people with CF not on CFTR modulators.

resultsAmB increased transepithelial Cl

conclusionsOur results provide the first evidence that AmB can impact a clinical biomarker in people with CF. These results encourage additional clinical studies in people with CF to determine whether small molecule anion channels can provide benefit.

Indexed as

Administration, IntranasalAmphotericin BAntifungal AgentsCells, CulturedCodon, NonsenseCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansRespiratory MucosaVoltage-Dependent Anion ChannelsAmphotericin BAntifungal AgentsCodon, NonsenseCystic Fibrosis Transmembrane Conductance RegulatorVoltage-Dependent Anion Channels

Identifiers

PMID33309058
PMCPMC8184863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.